Donidalorsen (1) – Dawnzera®
Hereditary angioedema, prophylaxis, ≥ 12 years
Characteristics
| Start date | 01.03.2026 |
|---|---|
| Resolution | 20.08.2026 – active procedure |
| INN | Donidalorsen |
| Brand name | Dawnzera® |
| Pharm. company | Otsuka Pharma GmbH |
| G-BA Procedure ID | D-1284 |
| Therapeutic area | Other diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions